Salute e Benessere

Veterinary Poc Hematology Diagnostics Market to Reach $1.7 Bn by 2027 in the…

Request Sample of the Report on Global Veterinary Poc Hematology Diagnostics Market 2030 - https://www.alliedmarketresearch.com/request-sample/A325653 Request Sample of the Report on Global Veterinary Poc Hematology Diagnostics Market 2030 -https://www.alliedmarketresearch.com/request-sample/A325653 Market Introduction Veterinary point-of-care (PoC) hematology diagnostics provide rapid and accurate blood analysis for animals, enabling veterinarians to diagnose conditions such as...
PR Newswire
22/04/2025

Kindeva bolsters executive team with Chief Quality Officer appointment

As a member of the Executive Leadership Team, Melanie will be responsible for further enhancing Kindeva's quality and compliance strategy, culture and capability. As a member of the Executive Leadership Team, Melanie will be responsible for further enhancing Kindeva's quality and compliance strategy, culture and capability. Commenting on Melanie's appointment,Milton Boyer, CEO of Kindeva, said, "Melanie's expertise and impressive track record in FDA, EMA, and ICH regulations will be...
PR Newswire
22/04/2025

BioProcess360 Partners Launches New Chromatography Company Through Transfer of…

ChromaGenix™ will combine industry expertise, academic innovation, and $35 million in planned investment to develop and scale next-generation purification technologies for gene therapies, vaccines, and immunotherapies ChromaGenix is launching to meet a growing global demand for scalable, application-specific purification solutions in the production of gene therapies, mRNA vaccines, exosomes, and lipid nanoparticles (LNPs). Its portfolio will be built on LigaTrap's proven ligand discovery...
Nasdaq GlobeNewswire
22/04/2025

Transactions under Novonesis' share buyback program

Please read the announcement in PDF Attachment 2025_19_Share_buyback_program
Nasdaq GlobeNewswire
22/04/2025

Tianlong Showcases Innovation at Prestigious International Biomedical Forum in…

Representing the innovation strength of our group, Jessica Wu, PhD in Biology and Product Manager of Tianlong, delivered a presentation titled "LigSeq Reagent Kits: Personalized Medication for Better Healthcare". The presentation introduced our latest achievements in precision diagnostics, highlighting how LigSeq technology is supporting more individualized and effective treatment pathways. Representing the innovation strength of our group,Jessica Wu, PhD in Biology and Product Manager…
PR Newswire
22/04/2025

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB).On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.The following transactions were executed under the program from April 14 to April 18, 2025: Trading Platform...
Nasdaq GlobeNewswire
22/04/2025

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and…

"TAG-72 is a validated target with overexpression in many high unmet need solid tumors. However, due to its non-internalizing nature, this target has remained unreachable by current ADCs and other therapies which require uptake by tumor cells to activate their anti-tumor activity. TGW101's highly differentiated profile enables controlled MMAE payload release and activation in the tumor microenvironment without internalization by tumor cells. This controlled drug release is achieved through…
PR Newswire
22/04/2025

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on…

MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE)-- BioNTech SE(Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.To access the live conference call via telephone, please register...
Nasdaq GlobeNewswire
22/04/2025

May 12-14 | Exploring the Future of the Beauty Industry in China

CBE will feature exciting new products from the world's top 100 beauty brands, including SHISEIDO, LG GROUP, CERAVE, PROYA GROUP, CHANDO GROUP, MATIS, LPG, BABOR, MATRISTAR, and PHYT'S and many others. CBE will feature exciting new products from the world's top 100 beauty brands, including SHISEIDO, LG GROUP, CERAVE, PROYA GROUP, CHANDO GROUP, MATIS, LPG, BABOR, MATRISTAR, and PHYT'S and many others. 2000 CBE Finished Product Exhibitors' Categories: 1500 CBE Supply Chain Exhibitors'...
PR Newswire
22/04/2025

AscellaHealth Demonstrates Leadership in Realizing the Full Potential of Novel…

DUBLIN and BERWYN, Pa., April22, 2025(GLOBE NEWSWIRE) --AscellaHealth, a global partner delivering customisable solutions to support the specialty pharmaceutical industry, proudly announces its participation in Advanced Therapies Integrates North 2025 , taking place on 30 April 2025 at the Usher Institute in Edinburgh. As a recognised leader in expanding access to innovative therapies for complex, chronic and rare diseases, AscellaHealth will be represented by Gillian Molloy, vice...
Nasdaq GlobeNewswire
22/04/2025

Pere Mañé Appointed as New CEO of Suanfarma

With a career spanning more than 30 years, Pere has held technical and strategic executive positions at leading pharmaceutical companies such asUquifa,Boehringer Ingelheim, andEsteve Química (Esteve Group). His experience ranges from technical and operational roles to executive positions such asGeneral ManagerandGroup Chief Industrial Operations Officer. Most recently, Pere played a key role in theindustrial transformation of Esteve, positioning its chemical...
PR Newswire
22/04/2025

Overcoming the Limits of Injectables: SYNERJET PRO™ Enters Pre-Market Stage in…

SYNERJET PRO™ overcomes these limitations by delivering active ingredients through high-velocity jet propulsion combined with simultaneous electroporation—completely needle-free. This approach enables fast, uniform delivery of therapeutic agents into the skin while remaining 100% non-invasive. It provides a comfortable and risk-free alternative to injections for safety-conscious patients, while also unlocks greater efficacy than traditional topical application, making it a breakthrough for both…
PR Newswire
22/04/2025

Noster research: Gut Microbiome-Derived HYA Shows Promise for Managing Blood…

Diabetes, particularly T1DM, requires careful management of blood sugar levels to prevent complications such as cardiovascular disease, nerve damage, and vision impairment. While insulin therapy is the cornerstone of T1DM treatment, postprandial hyperglycemia remains a challenge, increasing the risk of long-term health issues. Diabetes, particularly T1DM, requires careful management of blood sugar levels to prevent complications such as cardiovascular disease, nerve damage, and vision…
PR Newswire
22/04/2025

Noster research: The Anti-Obesity Potential of Gut Microbes in High-Sugar Diets

Obesity, driven by high sugar consumption, is a global health challenge. This study highlights the unique role of S. salivarius, a naturally occurring gut bacterium, in mitigating the effects of sucrose. Unlike other bacteria, S. salivarius produces large quantities of EPS—complex carbohydrates that the human digestive system cannot break down. These EPS act as prebiotics, feeding beneficial gut microbes that produce SCFAs, compounds known to regulate energy metabolism, reduce fat storage, and…
PR Newswire
22/04/2025

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start…

"We are delighted to have reached an important milestone of entering clinical development of OT-C001 following our strategic investments in Emercell since 2021," said Dr. C. Grace Yeh, Chairman and CEO of Onward Therapeutics,"This Phase 1 trial may validate Emercell's patented platform technology for meaningful clinical outcomes. Along with the continued optimization of industrial manufacturing, these efforts will strengthen our ability to form strategic partnerships and advance…
PR Newswire
22/04/2025

Invitation to Orion's Capital Markets Day on 22 May 2025

ORION CORPORATIONINVESTOR NEWS22 APRIL 2025 at 9.00 EEST Invitation to Orion's Capital Markets Day on 22 May 2025Orion invites analysts, institutional investors, bankers and media representatives to its Capital Markets Day on Thursday 22 May 2025. The event will be held at Event Venue Eliel, at Töölönlahdenkatu 2, Helsinki, Finland. During the afternoon, Orion's President & CEO, Liisa Hurme, CFO René Lindell, and other members of the Executive Management Board will...
Nasdaq GlobeNewswire
22/04/2025

Zelluna Reaches Major Milestone with Manufacturing Process Established in…

Establishing and locking down a manufacturing process marks an essential step towards the production of TCR-NK cell therapies for clinical development and future commercialization. Based on the established manufacturing process, hundreds of doses could be produced from a single manufacturing batch highlighting scalability and low cost of goods potential. Zelluna continues to advance its lead TCR-NK cell therapy candidate ZI-MA4-1 in preparation for a filing in the second half of 2025 to...
Nasdaq GlobeNewswire
22/04/2025

Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United…

USD 50 billion commitment includes new state-of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California and an additional site location to be announced soonInvestments will create more than 12,000 new jobs: 1,000 at Roche and more than 11,000 in support of new US manufacturing capabilities Roche already has a significant existing US presence with more than 25,000 employees, 15 R&D centres...
Nasdaq GlobeNewswire
22/04/2025

Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust…

Facing a challenging landscape, Venus Medtech reinforced its leadership in China's valvular therapy sector while achieving significant progress in operational efficiency and commercial profitability, mainly reflected in： Facing a challenging landscape, Venus Medtech reinforced its leadership inChina'svalvular therapy sector while achieving significant progress inoperational efficiency and commercial profitability, mainly reflected in： Cost Optimization Profitability Focus ...
PR Newswire
22/04/2025

FIELD MEDICAL CLOSES $40 MILLION SERIES A FINANCING TO REDEFINE PULSED FIELD…

"This financing is a pivotal milestone as we advance in redefining how electrophysiologists approach ablation therapy," said Steven Mickelsen, M.D., founder and chief executive officer of Field Medical. "With the support of our investors, we are accelerating the development of the FieldForce™ Ablation System, building on early clinical evidence, and moving closer to our commercial goal of expanding access to next-generation PFA solutions for cardiac ablation." "This…
PR Newswire
22/04/2025

Roche's HEMLIBRA Achieves Significant Uptake Across Key Hemophilia A Markets |…

Chugai/Genentech/Roche's HEMLIBRA (emicizumab) Overview Chugai/Genentech/Roche's HEMLIBRA (emicizumab) Overview HEMLIBRA is a bispecific antibody that targets both factor IXa and factor X, two key proteins in the body's natural blood clotting process. Bridging these proteins it helps restore clotting function in individuals with hemophilia A. HEMLIBRA is used as a preventive treatment and is administered as a ready-to-use subcutaneous injection. It can be given once a week, every two...
PR Newswire
21/04/2025

Resmed Names Salli Schwartz as Chief Investor Relations Officer

Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Resmed (NYSE: RMD, ASX: RMD ), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the...
Nasdaq GlobeNewswire
21/04/2025

Galapagos Announces Executive Leadership Updates

Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to continue as Chair of the Board of Directors, ensuring leadership continuity and long-term strategic guidance Mechelen, Belgium; April 21, 2025, 22:10 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a...
Nasdaq GlobeNewswire
21/04/2025

Jazz Pharmaceuticals Completes Acquisition of Chimerix

"Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs," said Bruce Cozadd, chairman and chief executive officer of Jazz. "Dordaviprone has the potential to become the first and only FDA-approved therapy for patients with H3 K27M-mutant diffuse glioma and offers a promising near-term commercial opportunity, if approved. We are excited to welcome Chimerix's talented team as we collectively continue to…
PR Newswire
21/04/2025
Altri  Comunicati